



PRODUCT: **Cablivi®**

COMPANY: Sanofi

THERAPEUTIC AREA & INDICATION:

Nanobody to treat adult acquired thrombotic
thrombocytopenic purpura (aTTP),
a rare blood disorder

ABOUT THE PRODUCT

Cablivi is a first-in-class humanized nanobody therapeutic approved for acquired Thrombotic Thrombocytopenic Purpura (aTTP), a life-threatening autoimmune blood disorder. Cablivi prevents pathological platelet aggregation by blocking glycoprotein Ib receptor on von Willebrand's Factor (vWF). In clinical trials, treatment with caplacizumab resulted in significantly shorter time to platelet count normalization, lower incidence of a composite endpoint of TTP-related death, recurrence, or a major thromboembolic event, and lower incidence of recurrence. As the world's first approved nanobody drug, Cablivi addresses significant unmet medical need in aTTP and represents a milestone in pharmaceutical sciences, paving the way for a new class of therapeutics.